Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for cochleostomy with neurovascular transplant for Ménière's disease, effective May 15, 2026. Here's what billing teams need to know before that date.
This CMS cochleostomy coverage policy update affects a narrow but high-stakes surgical procedure. The policy does not carry a numbered policy code in CMS's standard NCD or LCD framework. No specific CPT, HCPCS, or ICD-10 codes are listed in the policy data — we address what that means for your billing team below.
| Field | Detail |
|---|---|
| Payer | CMS / Centers for Medicare & Medicaid Services |
| Policy | Cochleostomy with Neurovascular Transplant for Ménière's Disease |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High — procedure-level coverage changes carry denial risk without proper documentation |
| Specialties Affected | Otolaryngology (ENT), Neurotology, Otology, Audiology (supporting diagnosis), General Surgery (billing/coding teams supporting ENT practices) |
| Key Action | Audit your charge capture and medical necessity documentation for cochleostomy claims before May 15, 2026 |
CMS Cochleostomy with Neurovascular Transplant Coverage Criteria and Medical Necessity Requirements 2026
CMS has modified its coverage policy for cochleostomy with neurovascular transplant as a treatment for Ménière's disease. This is a rare, invasive inner ear procedure. Before billing Medicare, your team needs to understand exactly what CMS requires to establish medical necessity.
Ménière's disease is a chronic inner ear disorder. It causes episodes of vertigo, fluctuating hearing loss, tinnitus, and aural fullness. Severe, refractory cases sometimes lead surgeons to consider cochleostomy — a procedure that involves creating an opening in the cochlea — in combination with neurovascular transplant techniques intended to address endolymphatic hydrops at its root.
The core question CMS's coverage policy asks is whether this intervention meets the bar for medical necessity. That means the procedure must be reasonable and necessary for the diagnosis or treatment of the patient's condition. For a procedure this specialized, that bar is high.
The policy data provided for this update does not include specific CPT or HCPCS codes. That is a red flag for your billing team. When CMS modifies a coverage policy without a published code list, it often means coverage turns entirely on documentation and diagnosis specificity — not just code selection.
Prior authorization is a real concern here. Even though this policy doesn't explicitly state prior authorization requirements in the available data, procedures classified at this level of surgical complexity and historical controversy almost always trigger prior auth review under Medicare Advantage plans. If your patients are on Medicare Advantage rather than traditional fee-for-service Medicare, check with each plan directly before scheduling.
Your documentation of medical necessity needs to show that conservative treatments failed. That means your records should reflect a documented trial of dietary management, diuretics, vestibular suppressants, and intratympanic therapy before cochleostomy was considered. Without that trail, you're looking at a claim denial.
The real issue here is that cochleostomy with neurovascular transplant sits in contested clinical territory. CMS has historically treated inner ear surgical procedures — particularly those outside cochlear implantation — with skepticism. A modification to this policy in 2026 likely signals that CMS is either tightening or clarifying what qualifies. Your compliance officer needs to review the full policy text before your first claim goes out.
CMS Cochleostomy with Neurovascular Transplant Exclusions and Non-Covered Indications
CMS's history with this procedure is important context. Procedures described as experimental or investigational get denied. Full stop.
Cochleostomy with neurovascular transplant has not achieved the same widespread clinical acceptance as cochlear implantation or endolymphatic sac decompression. If CMS's modification moves this procedure — or any variant of it — into an explicitly non-covered or investigational category, every claim you submit will be denied until you have a successful appeal or an ABN on file.
The policy data available does not specify which indications are excluded. That ambiguity is dangerous. A coverage policy that doesn't clearly define exclusions puts the documentation burden on your team. If you can't affirmatively demonstrate the claim meets covered criteria, assume it will be reviewed closely.
Bilateral cochleostomy or procedures performed outside the standard indication of refractory unilateral Ménière's disease are especially vulnerable. Document the laterality, the duration of disease, and the failure of prior treatment clearly in every claim.
If you're not sure how this policy modification applies to your patient mix, talk to your compliance officer before May 15, 2026.
Coverage Indications at a Glance
The policy data provided does not include a detailed breakdown of covered versus non-covered indications. The table below reflects what is clinically and historically consistent with CMS coverage policy for this procedure type. Treat this as a working framework — not a substitute for the full policy text.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Refractory unilateral Ménière's disease after failed conservative treatment | Coverage status determined by medical necessity documentation | Not listed in policy data | Must document failure of dietary, pharmacologic, and intratympanic therapy |
| Bilateral Ménière's disease | High denial risk | Not listed in policy data | Non-standard indication; requires strong clinical justification |
| Cochleostomy without neurovascular transplant component | Coverage status unclear under this policy | Not listed in policy data | May be addressed under a separate procedure code |
| Experimental or investigational variants | Not covered | Not listed in policy data | If CMS designates this procedure investigational, ABN required before service |
| Medicare Advantage plans | Varies by plan | Not listed in policy data | Confirm prior authorization requirements with each plan separately |
CMS Cochleostomy Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Pull every open or pending cochleostomy claim now. Before May 15, 2026, review any claims for cochleostomy with neurovascular transplant that are pending, appealed, or in pre-authorization. The effective date of May 15, 2026 means the modified policy governs all claims processed on or after that date. |
| 2 | Contact your Medicare Administrative Contractor (MAC) directly. Because this policy does not list specific CPT or HCPCS codes, your MAC is your best source for the exact coding guidance that applies in your jurisdiction. MACs often publish local coverage determinations (LCDs) that supplement or clarify CMS national policy. Call or check your MAC's website for any related LCD updates tied to this modification. |
| 3 | Audit your medical necessity documentation templates. Your pre-operative documentation must show the full conservative treatment history. Build a checklist: dietary sodium restriction, diuretics, vestibular suppressants, intratympanic steroid injections, and intratympanic gentamicin where applicable. If your ENT physicians aren't documenting this chain, your billing team will take the denial. |
| 4 | Update your ABN workflow for this procedure. If there's any question about whether this procedure meets CMS's modified coverage criteria for a specific patient, issue an Advance Beneficiary Notice of Noncoverage before the service. Cochleostomy with neurovascular transplant is not a last-minute ABN situation — this needs to be part of your pre-service workflow. |
| 5 | Verify prior authorization with every Medicare Advantage plan in your payer mix. Traditional Medicare fee-for-service and Medicare Advantage plans operate under different rules. A CMS national coverage policy modification doesn't automatically translate to consistent MA plan behavior. Call each plan. Get the prior auth requirement in writing. |
| 6 | Flag this for your compliance officer. The combination of a high-complexity surgical procedure, a coverage policy with no listed codes, and a modification type — not a new policy — means the change in language matters enormously. Your compliance officer needs to do a line-by-line comparison of what changed in the policy text. A one-word shift from "not covered" to "covered when medically necessary" changes everything. So does the reverse. |
| 7 | Train your coding team on cochleostomy-specific documentation requirements before May 15, 2026. Cochleostomy billing is not common. If your coders haven't touched this procedure recently, a quick refresher on operative report requirements — specifically the neurovascular transplant component — reduces your denial rate from the start. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Cochleostomy with Neurovascular Transplant Under CMS Policy
The policy data provided for this modification does not list specific CPT, HCPCS, or ICD-10 codes.
This is not a minor omission. Cochleostomy with neurovascular transplant billing requires your coding team to identify the correct procedure code from the CPT code set based on the operative report — and to confirm that code is recognized by your MAC under this policy. Do not bill based on assumptions.
What to Do Instead of Using a Code Table
Contact your MAC directly and ask for the covered CPT codes associated with this policy. Also request any applicable ICD-10-CM diagnosis codes they require to support medical necessity for Ménière's disease claims at this level of surgical intervention.
When you receive that information, document it internally and tie it to the May 15, 2026 effective date. That creates an audit trail showing your team acted on the modified policy in good time.
Relevant Clinical Context for Code Research
When working with your coding team or MAC to identify the right codes, the key clinical elements to account for are:
- The cochleostomy itself (surgical opening of the cochlea)
- The neurovascular transplant component (this distinguishes the procedure from standard cochleostomy and may require a separate code or modifier)
- The Ménière's disease diagnosis (endolymphatic hydrops, unilateral versus bilateral)
- Any associated procedures performed in the same operative session
Your coding team should also verify whether this procedure has an established CPT code or falls under an unlisted procedure code — which triggers additional documentation requirements and manual review by CMS.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.